Next Phase Newsletter

The Pharma is a global pharmaceutical company headquartered in Japan and is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets.

In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, under the Group’s 2025 Vision, the Pharma Research and Development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology, with additional focus on new horizon areas, such as pain management, neurodegenerative diseases, heart and kidney conditions, and rare diseases. The Pharma is currently looking for partnering and in-licensing opportunities across the globe.

The Pharma is currently looking for innovative therapeutics targeting the following priority areas: oncology, pain management, cardiovascular disease, CNS, and rare diseases. Other interest areas include novel therapeutic targets and approaches for the gut microbiome that can modulate disease outcome, cell therapeutics for serious diseases including Stroke/TIA, PAD/CLI and hepatic cirrhosis, and novel therapies for hematological diseases, especially for anemic disorders with erythropoietin resistance. The Pharma is open to biologics or small molecules, with an increased interest in new platform technologies. The following areas are currently out of focus: diabetes, hypertension, dyslipidemia, psychiatric diseases, and immunodeficiency.

The Pharma partners with privately held life science companies with experienced management teams and innovative technologies in the abovementioned areas.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The pharma is headquartered in the US, with research sites also in Boston/Worcester, Bay area and Germany. The firm forms partnerships with development stage biotech companies via a variety of structures, including strategic venture investments, in-licensing, collaborations, and M&A. The company looks globally for opportunities.

The pharma focuses on transformative therapeutic assets in oncology (including immuno-oncology), immunology and autoimmune diseases, and neurodegenerative diseases (priority areas being Alzheimer’s disease and Parkinson’s disease) & psychiatric diseases (including mood disorders). The firm is also interested in therapeutics addressing fibrotic diseases and some infectious diseases such as HBV. The pharma is open to biologics and cell / gene therapies in addition to small molecules. The pharma will consider assets at any stage of development, but is particularly interested in outreach from companies developing early stage assets and technologies.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

The firm is a venture capital founded in 2006 and based on the West Coast. The firm is currently investing out of its second fund vintage 2013 fund and has a total of $130 million in assets under management. The firm makes equity investments of up to $4 million into companies over the lifetime of the investment in both the seed and venture stage. The firm is most interested in companies located in California especially for seed stage deals, but will consider investments throughout the United States. The firm is actively seeking new investment opportunities.

The firm is looking for companies in the Medical Device space. The firm is looking for companies in all stages of development and across areas of medicine including cardiovascular and general surgery, orthopedic surgery, cardiology, radiology, oncology, obesity, gynecology, sleep disorders and more including orphan indications.

The firm is looking for companies with experienced management teams though the management team need not be complete. The firm is able to provide assistance in filling gaps in these teams through the firm’s connections in the industry. The firm looks to take a board seat into companies following investment

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

An investment management firm based in Tianjin, China is managing multiple funds and is engaged in equity investment, asset management, merger and acquisition across several industries including healthcare. The firm’s healthcare portfolio includes some large pharmaceutical companies in China. The size of investment varies depending on the deal, but the firm is investing from a 1 billion RMB fund for healthcare. The firm is currently seeking equity investment and licensing opportunities in China and the US. The firm is looking for companies with a China angle and has experience helping companies obtain CFDA approval.

Within healthcare, the firm is interested in medical devices, IVD, medical equipment, home-care products, and other healthcare-related technologies. The firm considers products that have at least completed prototype. The firm prefers products that have already obtained FDA clearance or approval, but it is happy to work with companies who are ~1 year away from FDA approval as well. In terms of indication areas, the firm is interested in diseases with large market potential in China, including oncology, reproductive health, cardiovascular diseases, and diabetes and metabolic disorders.

The firm seeks to work with experienced teams with strong sector knowledge. The firm is looking for products with a China angle and may request distribution rights in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

A Venture Capital company was founded in 1996 with offices in London, San Francisco and Geneva. The firm is currently making investments out of its $200 million life science focused fund. The fund is backed by Johnson and Johnson and GSK who are members of the fund’s Scientific Advisory Board. The firm’s investment size is variable although they look to invest in companies who are able to reach a substantial value inflection point and exit with $15-$20 million in total investment over 4-6 years. The firm is looking for companies located around the globe. The firm is actively seeking new investment opportunities.

The firm is currently seeking to invest in companies developing therapeutics. The firm is generally agnostics across indication areas and technology types and is open to reviewing small molecules and biologics as well as cell and gene therapy. The firm is looking for companies with a lead asset anywhere from the Pre-clinical phase to Phase II of clinical trials. The firm’s main investment strategy is to back/create virtual companies focused around a single therapeutic asset. The firm is able to invest in particularly early stages of companies working with antibodies and biologics as they have significant domain expertise in these areas. For companies working with novel mechanisms of action the firm requires there be a strong understanding of the underlying sciences, and for companies working with pre-existing pathways or technologies there must be clear evidence of differentiation.

The firm is looking for companies where the founders have some involvement, either in management or as advisors/consultants to ensure the project as the scientific support required to succeed. The firm looks to play an active role in companies and takes a board seat following investment. The firm is willing to invest in both private and publically held companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

An evergreen strategic venture capital fund of a Big Pharma closed $100 million in 2013 and is managing by a small, dedicated team based in Cambridge, Massachusetts and Palo Alto, California. The fund focuses on investments in companies developing pioneering bioelectronic medicines/ neuromodulation device and related enabling technologies. The initial investments are typically ranging from $5-$7 million in Series A, and the fund will also consider follow-on investments. The firm looks for investment opportunities globally.

A fund dedicated to advancing bioelectronic medicines and is looking to invest in high-return opportunities in three areas: (1) Teams pursuing new therapies for existing peripheral neurostimulation devices. (2) Teams developing novel bioelectronic medicine technologies for existing neurostimulation therapies. (3) Companies introducing advanced technologies that are enabling for bioelectronics medicines. The firm is particularly interested in improved neural interfaces, novel power sources and wireless powering technology, ultra-low power chip architectures, sensors that can close-the-loop for adaptive therapies and new implantation and imaging methods. The firm is stage agnostic.

The firm typically will take board of directors or board observer seat, but it is not necessary. The fund exclusively invests in privately-held companies and primarily in pre-revenue companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.